Table 2.
Genome matched treatments (GMT)
| Drug Status | Cancer Category | Primary Cancer Site | Drug Class | Variant Class | Variants |
|---|---|---|---|---|---|
| FDA-approved tumor type (154) | Lung (33) | Lung | PD-1/L1 inhibitor (25) | MAPK pathway | KRAS (2) |
| PD-L pos | PD-L1 expression (15); PD-L1 expression, TMB-H (1) | ||||
| TMB high | TMB-H (7) | ||||
| MAPK inhibitor (6) | MAPK pathway | KRAS (1); BRAF (4) | |||
| other variant | MAP2K1 (1) | ||||
| EGFR inhibitor (2) | EGFR | EGFR (2) | |||
| Breast (38) | Breast | Her2/neu inhibitor (15) | ERBB2 | ERBB2 (15) | |
| CDK4/6 inhibitor (11) | Cell cycle reg | CDKN2A, ESR1 (1); CCND1, ESR1 (1); CCND1, PIK3CA (1); CCND1 (5) | |||
| PI3K/AKT/MTOR pathway | ESR1, PIK3CA (1); PIK3CA (1) | ||||
| other variant | FGFR1 (1) | ||||
| PI3K/AKT/MTOR inhibitors (9) | PI3K/AKT/MTOR pathway | PIK3CA (8); RPS6KB1 (1) | |||
| PD-1/L1 inhibitor (2) | PD-L pos | PD-L1 expression (2) | |||
| PARP inhibitor (1) | other variant | PALB2 (1) | |||
| Gynecologic (20) | Cervix | PD-1/L1 inhibitor (1) | PD-L pos | PD-L1 expression, TMB-H (1) | |
| Endometrium | PD-1/L1 inhibitor (5) | other variant | MSI: Instable, TMB-H (2) | ||
| PD-L pos | PD-L1 expression, TMB-H (1); PD-L1 expression (1) | ||||
| TMB high | TMB-H (1) | ||||
| Fallopian Tubes | PARP inhibitor (8) | non BRCA DDR | BARD1 (1); NBN (1) | ||
| BRCA | BRCA2 (2); BRCA1 (4) | ||||
| Ovaries | PARP inhibitor (6) | non BRCA DDR | ATM (2); ARID1A, PTEN (1) | ||
| BRCA | BRCA1 (1) | ||||
| MAPK pathway | KRAS (2) | ||||
| Gastroesophageal (25) | Esophagus | PD-1/L1 inhibitor (12) | ERBB2 | ERBB2 (1) | |
| other variant | MSI: Instable, PD-L1 expression, TMB-H (2) | ||||
| PD-L pos | PD-L1 expression, TMB-H (1); PD-L1 expression (8) | ||||
| Her2/neu inhibitor (7) | ERBB2 | ERBB2 (7) | |||
| Gastric | Multi-kinase inhibitor (2) | other variant | KIT (2) | ||
| PD-1/L1 inhibitor (2) | PD-L pos | PD-L1 expression (2) | |||
| Her2/neu inhibitor (1) | ERBB2 | ERBB2 (1) | |||
| Other | PD-1/L1 inhibitor (1) | other variant | MSI: Instable, PD-L1 expression, TMB-H (1) | ||
| Urinary (12) | Bladder | PD-1/L1 inhibitor (3) | PD-L pos | PD-L1 expression, TMB-H (1); PD-L1 expression (2) | |
| Other | PD-1/L1 inhibitor (2) | PD-L pos | PD-L1 expression (2) | ||
| Renal | Multi-kinase inhibitor (5) | other variant | VHL (5) | ||
| PD-1/L1 inhibitor (2) | PD-L pos | PD-L1 expression (2) | |||
| Colon (7) | Colon | PD-1/L1 inhibitor (6) | other variant | MSI: Instable, PD-L1 expression, TMB-H (1); MSI: Instable (1) | |
| PD-L pos | PD-L1 expression (2) | ||||
| TMB high | TMB-H (2) | ||||
| EGFR inhibitor (1) | EGFR | EGFR (1) | |||
| Liver/biliary (2) | Liver | PD-1/L1 inhibitor (2) | PD-L pos | PD-L1 expression (2) | |
| Melanoma (10) | Melanoma, mucous membranes (GI and other) | PD-1/L1 inhibitor (1) | MAPK pathway | BRAF (1) | |
| Melanoma, ocular | PD-1/L1 inhibitor (1) | PD-L pos | PD-L1 expression (1) | ||
| Melanoma, skin | MAPK inhibitor (4) | MAPK pathway | BRAF (4) | ||
| PD-1/L1 inhibitor (3) | PD-L pos | PD-L1 expression (2) | |||
| TMB high | TMB-H (1) | ||||
| Other | PD-1/L1 inhibitor (1) | MAPK pathway | BRAF (1) | ||
| Pancreas (2) | Pancreas | PARP inhibitor (2) | BRCA | BRCA2 (2) | |
| Prostate (3) | Prostate | PARP inhibitor (3) | non BRCA DDR | ARID1A (1) | |
| BRCA | BRCA2, RAD51C (1); BRCA2 (1) | ||||
| Other (2) | Other | PD-1/L1 inhibitor (2) | PD-L pos | PD-L1 expression (2) | |
| FDA-approved different tumor type (64) | Lung (7) | Lung | Multi-kinase inhibitor (3) | other variant | MET (1); FGFR1 (1); FGFR2 (1) |
| PARP inhibitor (1) | non BRCA DDR | FANCI (1) | |||
| PI3K/AKT/MTOR inhibitors (1) | PI3K/AKT/MTOR pathway | PTEN (1) | |||
| Mesothelioma, Lung | PD-1/L1 inhibitor (1) | PD-L pos | PD-L1 expression (1) | ||
| PI3K/AKT/MTOR inhibitors (1) | PI3K/AKT/MTOR pathway | PIK3CA (1) | |||
| Breast (1) | Breast | Multi-kinase inhibitor (1) | other variant | KIT (1) | |
| Gynecologic (12) | Cervix | PARP inhibitor (1) | non BRCA DDR | FANCM (1) | |
| Endometrium | PARP inhibitor (4) | BRCA | BRCA2 (2) | ||
| non BRCA DDR | RAD50 (1); ARID1A (1) | ||||
| Her2/neu inhibitor (1) | ERBB2 | ERBB2 (1) | |||
| Fallopian Tubes | CDK4/6 inhibitor (1) | Cell cycle reg | CCNE1 (1) | ||
| Her2/neu inhibitor (1) | ERBB2 | ERBB2 (1) | |||
| Other | Multi-kinase inhibitor (1) | other variant | FGF23, FGF6 (1) | ||
| Ovaries | CDK4/6 inhibitor (1) | Cell cycle reg | CDKN2A (1) | ||
| FGFR inhibitor (1) | other variant | FGFR1 (1) | |||
| Uterus | PARP inhibitor (1) | non BRCA DDR | FANCM, KMT2D (1) | ||
| Gastroesophageal (2) | Esophagus | PI3K/AKT/MTOR inhibitors (1) | PI3K/AKT/MTOR pathway | STK11 (1) | |
| Gastric | EGFR inhibitor (1) | EGFR | EGFR (1) | ||
| Brain (16) | Brain | PD-1/L1 inhibitor (6) | other variant | IDH1 (2) | |
| PD-L pos | PD-L1 expression (4) | ||||
| CDK4/6 inhibitor (3) | Cell cycle reg | CDK4, PIK3CB (1); CDKN2A (1); CDK4 (1) | |||
| EGFR inhibitor (3) | EGFR | EGFR (3) | |||
| PARP inhibitor (2) | BRCA | BRCA2 (1) | |||
| non BRCA DDR | CHEK2 (1) | ||||
| Her2/neu inhibitor (1) | EGFR | EGFR (1) | |||
| Multi-kinase inhibitor (1) | other variant | PDGFRA (1) | |||
| Urinary (5) | Bladder | PARP inhibitor (1) | MAPK pathway | ATR, NRAS, PIK3CA, WRN (1) | |
| PI3K/AKT/MTOR inhibitors (1) | PI3K/AKT/MTOR pathway | TSC1 (1) | |||
| Other | PD-1/L1 inhibitor (1) | PD-L pos | PD-L1 expression (1) | ||
| other drug (1) | other variant | PTCH1 (1) | |||
| Renal | FGFR inhibitor (1) | other variant | FGFR3 (1) | ||
| Colon (4) | Colon | PARP inhibitor (2) | BRCA | BRCA2 (1) | |
| MAPK pathway | NRAS (1) | ||||
| MAPK inhibitor (1) | MAPK pathway | BRAF (1) | |||
| PD-1/L1 inhibitor (1) | MAPK pathway | KRAS (1) | |||
| Liver/biliary (5) | Bile Duct | FGFR inhibitor (2) | other variant | FGFR3 (1); FGFR2 (1) | |
| other drug (1) | other variant | IDH2 (1) | |||
| Gall Bladder | Multi-kinase inhibitor (1) | other variant | KDR (1) | ||
| Other | Multi-kinase inhibitor (1) | other variant | FGF6 (1) | ||
| Pancreas (5) | Pancreas | PD-1/L1 inhibitor (3) | PD-L pos | PD-L1 expression (3) | |
| PARP inhibitor (1) | non BRCA DDR | ATM (1) | |||
| MAPK inhibitor (1) | MAPK pathway | KRAS (1) | |||
| Prostate (1) | Prostate | PD-1/L1 inhibitor (1) | PD-L pos | PD-L1 expression (1) | |
| Other (6) | Other | PD-1/L1 inhibitor (2) | PD-L pos | PD-L1 expression (2) | |
| MAPK inhibitor (1) | MAPK pathway | BRAF (1) | |||
| CDK4/6 inhibitor (1) | Cell cycle reg | CDK4 (1) | |||
| Unknown | PARP inhibitor (1) | Cell cycle reg | CDK12 (1) | ||
| PD-1/L1 inhibitor (1) | PD-L pos | PD-L1 expression (1) | |||
| Clinical trial (22) | Lung (3) | Lung | MAPK inhibitor (3) | MAPK pathway | KRAS (3) |
| Breast (3) | Breast | Her2/neu inhibitor (2) | ERBB2 | ERBB2 (2) | |
| PARP inhibitor (1) | non BRCA DDR | ARID1A (1) | |||
| Gynecologic (2) | Endometrium | PI3K/AKT/MTOR inhibitors (1) | PI3K/AKT/MTOR pathway | AKT1 (1) | |
| MAPK inhibitor (1) | MAPK pathway | BRAF (1) | |||
| Gastroesophageal (1) | Gastric | Multi-kinase inhibitor (1) | other variant | KIT (1) | |
| Brain (4) | Brain | EGFR inhibitor (2) | EGFR | EGFR (2) | |
| CDK4/6 inhibitor (1) | Cell cycle reg | CDKN2A (1) | |||
| MAPK inhibitor (1) | MAPK pathway | NF1 (1) | |||
| Colon (4) | Colon | Her2/neu inhibitor (2) | ERBB2 | ERBB2 (2) | |
| MAPK inhibitor (2) | MAPK pathway | NRAS (2) | |||
| Liver/biliary (3) | Bile Duct | Her2/neu inhibitor (2) | ERBB2 | ERBB2 (2) | |
| FGFR inhibitor (1) | other variant | FGFR2 (1) | |||
| Pancreas (1) | Pancreas | PD-1/L1 inhibitor (1) | PD-L pos | PD-L1 expression (1) | |
| Other (1) | Other | other drug (1) | other variant | RET (1) |
The matching process is described in detail in the supplementary materials, but briefly, GMT was defined as either: (a) patient received a drug with an FDA label that included a variant or biomarker identified by their GTT; and/or (b) a patient received a targeted drug that was listed on their GTT report. GMTs were further categorized into “FDA-approved within tumor type (on-label)”, “FDA-approved in different tumor type (off-label)” or “Clinical trial”. There were 240 GMTs among the 206 patients. N of cases is displayed in ().